oncolog lead show
maintain buy rate upgrad tp
deriv tp base estim ep
forward look price-to-earnings give
upsid potenti expect
revenu growth
estim base follow factor strong growth
keytruda gardasil bridion anim health
strong growth oncolog product pipelin
merck provid strong start increas
revenu growth y/i due growth
keytruda gardasil bridion anim health segment
merck announc result phase studi
show keytruda combin pemetrex
platinum chemotherapi reduc risk death half
compar chemotherapi alon first-lin treatment
advanc non-squam first-lin lung cancer data
review regulatori author
unit state europ japan
pharmaceut segment revenu increas y/i
increas due growth
oncolog hospit acut care diabet partial
off-set lower sale virolog on-going impact
loss market exclus sever product
keytruda revenu increas
compar increas revenu
due growth volum market merck continu
launch keytruda multipl new indic global
compani namemerck compani inc tickermrkstock ratingbuyunchangedindustri viewoverweightpositivepric jun week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispidearavindra merck compani inc june
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
lynparza revenu
approv fda japanes ministri labour
welfar januari certain type cancer
total revenu anim health product increas
compar
increas revenu due higher sale livestock
product particularli rumin poultri product
net incom decreas
compar ep decreas
compar due
aggreg charg relat format
collabor eisai co ltd non-gaap ep
compar
price-to-earnings trade averag price-to-earnings
averag till even went
current price-to-earnings
fell averag price-to-earnings even touch
expect forward price-to-earnings multipl
expect merck revenu grow
estim non-gaap ep
respect given buy rate stock
tp due strong perform
growth pipelin special oncolog busi
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jul ex-dividend date last split factor new per last split date feb inform merck compani inc june
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
incom statement item total gross research develop sell gener administr sg oper depreciation- oper profit interest incom special interest incom minor incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli merck compani inc june
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item merck compani inc june
provid oper activ compar
provid oper activ includ up-front payment made compani relat
format collabor eisai
use invest activ compar cash provid invest activ
chang due lower proce sale secur
invest well mileston payment relat collabor bayer partial
off-set lower purchas secur invest use cash prior year quarter
acquisit busi
use financ activ compar cash provid financ
activ chang due lower short-term borrow higher payment debt
partial off-set lower purchas treasuri stock
depreciation- defer incom oper increas decreas increas decreas current assets- decreas increas decreas increas current decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant equipment- net invest financ activitiesissu debt- issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end total revenu increas
compar
gross margin
compar
merck strong start due strong growth keytruda gardasil
bridion anim health total revenu increas y/i
gaap ep decreas y/i due aggreg
charg relat format collabor eisai co ltd
total revenu increas compar
increas revenu due higher sale
oncolog franchis reflect strong growth keytruda merck
hospit acut care franchis due bridion inject noxafil
higher sale diabet franchis
papillomaviru hpv vaccin gardasil/gardasil nuvar
anim health product also contribut sale growth quarter
increas revenu partial off-set declin virolog franchis
due lower sale hepat viru hcv treatment zepati also due
lower sale zostavax on-going effect gener biosimilar
competit cardiovascular product zetia vytorin immunolog product
remicad well lower sale product within diversifi brand
franchis also partial off-set revenu growth
global effort toward health care cost contain continu exert
pressur product price market access world-wide unit state
price pressur continu mani merck product sever
intern market government-mand price action reduc
price gener patent drug addit auster measur
neg affect merck revenu perform
cog increas compar
cost includ expens amort intang
asset record connect busi acquisit
gross margin compar
increas due lower net impact amort intang
asset intang asset impair charg restructur cost
unfavor affect gross margin ppt compar ppt
improv gross margin partial off-set amort
unfavor manufactur varianc result part june
cyber-attack well unfavor effect foreign exchang
non-gaap gross margin compar
decreas non-gaap gross margin due amort
unfavor manufactur varianc part result june cyber-
attack well unfavor effect foreign exchang
sg expens increas compar
increas expens reflect unfavor effect foreign
exchang higher administr cost reflect priorit
invest growth product
 expens increas compar
increas due aggreg charg relat
format collabor eisai unfavor effect foreign
exchang increas clinic develop spend invest earli drug
develop partial off-set lower licens cost
non-gaap expens decreas compar
previou year quarter decreas reflect lower licens cost partial
off-set unfavor effect foreign exchang increas clinic
develop spend invest earli drug develop
incom expens net incom compar
incom non-gaap incom expens net
incom compar incom non-
incom expens net reflect gain legal settlement
recognit unreal gain secur result adopt
new account standard equiti invest
effect incom tax rate reflect unfavor impact
aggreg charg relat format eisai
collabor tax benefit recogn
net incom decreas compar
ep decreas compar
non-gaap ep compar
compar
gaap ep decreas
compar
compar
merck oper two busi segment pharmaceut anim
segment includ human health pharmaceut
vaccin product health pharmaceut product consist
therapeut prevent agent gener sold prescript
treatment human disord vaccin product consist prevent
pediatr adolesc adult vaccin primarili administ physician
pharmaceut segment revenu increas
compar revenu includ posit impact
foreign exchang increas due growth
oncolog hospit acut care diabet partial off-set
lower sale virolog on-going impact loss market
exclus sever product
total revenu pharmaceut segment decreas
compar total intern
revenu increas compar
growth oncolog due signific increas sale keytruda
reflect merck continu launch new indic global
strong momentum treatment patient nsclc keytruda
approv first-lin set oncolog sale also
reflect allianc revenu relat lynparza approv
fda januari
keytruda revenu increas compar
increas revenu due growth
volum market merck continu launch keytruda multipl
increas
compar
increas
compar
keytruda revenu increas
compar sale unit state continu
build across multipl approv indic particular
treatment nsclc reflect continu adopt keytruda
first-lin set monotherapi patient metastat nsclc
well uptak keytruda combin pemetrex
carboplatin indic includ melanoma head neck cancer
bladder cancer also contribut growth
total intern revenu keytruda increas
compar increas revenu
due posit perform recent approv indic
particularli treatment nsclc reimburs establish
lynparza revenu approv fda
japanes ministri labour welfar januari
certain type cancer
perform vaccin busi due higher sale
gardasil/gardasil vaccin prevent certain cancer
diseas caus hpv
gardasil revenu increas compar
increas revenu due growth asia
pacif region due commerci launch china growth europ
partial off-set lower sale unit state
gardasil revenu decreas
compar decreas gardasil/gardasil
sale unit state due on-going impact transit
regimen regimen
keytruda revenu
 increas
compar
increas
compar
gardasil intern revenu increas
compar
proquad/m-m-r ii /varivax revenu increas
compar increas revenu due volum
growth intern market higher price total revenu
 total intern revenu increas
compar
vaccin perform neg affect signific decreas sale
zostavax vaccin prevent herp zoster revenu
decreas compar
decreas due approv competitor product receiv
preferenti recommend advisori committe
immun practic octob merck anticip futur sale
zostavax continu unfavor affect competit
zostavax revenu decreas
intern revenu
growth hospit acut care reflect strong global demand bridion
inject medicin revers neuromuscular blockad adult
bridion revenu increas compar
sale growth due volum growth
certain european market
bridion revenu increas compar
total intern revenu increas
compar
revenu zostavax
decreas
compar
increas
compar
total revenu simponi increas
compar increas revenu due volum
growth europ
total revenu remicad decreas
compar
total revenu isentress isentress hd declin
compar sale declin due lower
demand unit state competit price pressur europ
latin america region particularli brazil total revenu
declin compar total
intern revenu
total revenu zepati declin
compar declin revenu due
unfavor effect increas competit declin patient volum
market particularli unit state substanti declin
 zepati revenu combin unfavor adjust rebat
reserv result recognit sale zepati
merck anticip sale zepati futur continu
materi advers affect competit lower patient volum
total global sale zetia vytorin atozet declin
compar previou year quarter foreign exchang
favor affect global sale perform global
sale declin due declin sale sale declin due
lower volum price zetia vytorin result gener
total revenu ezetrol european market inegi
total revenu
zepati declin
compar
total global sale
zetia vytorin atozet
declin
compar
previou year
singulair revenu declin compar
nasonex revenu declin compar
dulera revenu declin compar
total revenu januvia janumet increas
compar increas revenu due
higher demand intern market sale declin
due continu price pressur partial
off-set volum growth well favor adjust rebat reserv
total revenu
januvia janumet
increas
compar
total revenu
nuvar increas
compar
total revenu nuvar increas
compar increas due higher sale
 due higher price well time custom purchas
unfavor affect sale patent provid market
exclus nuvar expir april compani anticip
signific declin nuvar sale futur period result gener
anim segment includ pharmaceut vaccin product
prevent treatment control diseas major farm companion
anim speci anim health segment met criteria separ
report becam report segment
total revenu anim health product increas
compar anim health sale affect
competit frequent introduct gener product
increas revenu due higher sale livestock product
particularli rumin poultri product anim health sale growth
also driven higher sale companion anim product driven larg
total revenu livestock increas
compar total revenu
compar total intern revenu
compar
total revenu companion anim increas
compar total revenu
compar total intern
revenu compar
total revenu
increas
compar
total revenu
increas
compar
merck expand focu oncolog advanc
develop program keytruda therapi lynparza
parp inhibitor co-develop co-commerci
astrazeneca merck recent present pivot phase data keytruda
american associ cancer research annual meet
merck eisai enter strateg collabor world-wide co-
develop co-commerci lenvima oral avail
tyrosin kinas inhibitor discov eisai eisai merck develop
commerci lenvima jointli monotherapi combin
keytruda
merck announc result phase trial evalu
keytruda combin pemetrex cisplatin carboplatin
first-lin treatment metastat non-squam non-smal cell lung
cancer nsclc find show combin significantli
improv overal surviv os reduc risk death half compar
chemotherapi alon pre-specifi exploratori analys os benefit
observ regardless express three categori
evalu
fda grant prioriti review supplement biolog licens
applic sbla keytruda combin pemetrex
platinum chemotherapi first-lin treatment patient
metastat non-squam nsclc pdufa date sept
merck announc follow valid european medicin
agenc ema central review process begun merck type ii
variat seek approv keytruda combin
pemetrex platinum cisplatin carboplatin first-lin treatment
patient metastat non-squam nsclc applic
accept review base os progression-fre surviv data
phase trial
merck expand focu
oncolog
advanc
keytruda
therapi lynparza
parp inhibitor co-
develop co-
commerci
fda accept
review new sbla
keytruda
treatment previous
treat patient
recurr metastat
head neck squamou
cell carcinoma base
data phase
sbla grant
prioriti review
keytruda
treatment patient
advanc cervic
cancer diseas
progress
merck announc phase trial evalu keytruda
monotherapi first-lin treatment local advanc metastat
nsclc includ non-squam squamou histolog met primari
endpoint os interim analysi conduct independ data
monitor committe demonstr treatment keytruda
result significantli longer os platinum-bas chemotherapi
carboplatin plu paclitaxel carboplatin plu pemetrex patient
tumor proport score tp percent
fda accept review new sbla keytruda treatment
previous treat patient recurr metastat head neck
squamou cell carcinoma base data phase
trial fda set pdufa date dec
merck european organ research treatment cancer
eortc announc find phase
trial investig keytruda adjuv therapi resect high-risk stage
melanoma result studi show keytruda significantli
prolong recurrence-fre surviv reduc risk diseas recurr
death compar placebo overal studi popul
merck incyt corpor announc extern data monitor
committe edmc review pivot phase
studi result evalu epacadostat combin keytruda
patient unresect metastat melanoma determin
studi meet primari endpoint improv overal
popul compar keytruda monotherapi studi second
primari endpoint os also expect reach statist signific
base result recommend edmc studi
stop safeti profil observ
consist observ previous report studi epacadostat
combin keytruda
fda accept new sbla grant prioriti review keytruda
treatment patient advanc cervic cancer diseas
progress chemotherapi fda set pdufa date
sbla keytruda treatment adult pediatr patient
refractori primari mediastin b-cell lymphoma
relaps two prior line therapi remain review
fda fda extend pdufa date day juli
due addit data analys submit merck
committe medicin product human use ema adopt
posit opinion recommend market author lynparza
use mainten therapi patient platinum-sensit relaps
high grade epitheli ovarian fallopian tube primari periton cancer
complet respons partial respons platinum-bas
ema valid review market author applic
lynparza use patient deleteri suspect deleteri brca
metastat breast cancer previous treat
chemotherapi neoadjuv adjuv metastat set
first regulatori submiss parp inhibitor breast cancer europ
januari lynparza approv fda use treatment
brca -mutat metastat breast cancer becom first
parp inhibitor approv beyond ovarian cancer
fda grant orphan drug design selumetinib mek
inhibitor co-develop astrazeneca treatment
merck viralyt limit sign definit agreement
propos merck acquir viralyt australian publicli trade
compani focus oncolyt immunotherapi treatment rang
cancer upon complet transact merck gain full right
sbla keytruda
treatment
adult pediatr
patient refractori
cell lymphoma
relaps two
prior line
therapi remain
review fda
drug design
inhibitor co-
develop
astrazeneca
treatment
merck also continu advanc vaccin hiv infecti diseas
merck announc begin two phase studi
investig polyval conjug vaccin prevent
pneumococc diseas first studi evalu safeti toler
immunogen follow pneumococc vaccin polyval
one year later healthi adult subject year age older second
studi evalu safeti toler immunogen
follow pneumococc vaccin polyval administ eight week
later adult infect hiv result phase phase studi
present intern societi pneumococci
merck present data robust hiv pipelin includ doravirin
late-stag investig non-nucleosid revers transcriptas inhibitor
investig nucleosid revers transcriptas transloc
inhibitor confer retrovirus opportunist infect
doravirin current review ema fda pdufa
date oct unit state
merck announc pivot phase studi relebactam merck
investig beta-lactamas inhibitor combin
imipenem/cilastatin demonstr favor overal respons
treatment certain imipenemnon-suscept bacteri infect
primari endpoint lower treatment-emerg nephrotox kidney
toxic secondari endpoint compar colistin colistimeth
sodium plu imipenem regimen base result compani plan
submit new drug applic fda
merck announc
begin two phase
studi
vaccin
prevent
tabl show pipelin product develop differ phase
phase reviewcanc keytruda advanc solid tumor cutan squamou cell carcinoma ovarian lenvima biliari tract endometri non-small-cel lungbacteri infect relebactam imipenem/cilastatin octob molecular entities/vaccineshiv doravirin eu doravirine/lamivudine/tenofovir disoproxil fumar eu pediatr hexaval combin vaccin keytruda breast octob colorect novemb esophag decemb gastric may eu head neck novemb eu hepatocellular may nasopharyng april renal octob small-cel lung may lynparza pancreat decemb prostat april selumetinib thyroid june supplement filingscanc keytruda combin carboplatin pemetrex in- cancer eu first non-squam non-small-cel lung relaps refractori primari mediastin b-cell- lymphoma pmbcl second cervic cancer second head neck squamou cell carcinoma lynparza second metastat breast cancer eu broader approv ovarian cancer lenvima hepatocellular cancer eu hiv infect march vaccin march failur vericiguat septemb zoster inactiv vzv vaccin decemb develop collabor develop current hold investig pediatr hexaval combin vaccin develop approv commerci partnership merck sanofi novemb fda issu respect compani work provid addit data request fda merck compani inc june
merck expect revenu includ
posit impact foreign exchang
ep expect non-
ep expect includ neg
impact foreign exchang
non-gaap tax rate expect
non-gaap oper expens expect increas y/i due increas
 spend
merck start year strong perform quarter
due growth keytruda gardasil bridion anim health total
revenu increas y/i ep decreas y/i
due aggreg charg relat format
collabor eisai co ltd non-gaap ep compar
merck announc result phase studi show
keytruda combin pemetrex platinum chemotherapi
reduc risk death half compar chemotherapi alon first-
line treatment advanc non-squam first-lin lung cancer data
review regulatori author unit
state europ japan
keytruda revenu increas compar
lynparza revenu
approv fda japanes ministri labour welfar
januari certain type cancer total revenu anim health
product increas compar
ytd stock perform roe roa
revenu
impact foreign
merck start year
strong
perform
quarter due growth
bridion anim
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
gross margin increas reduc cog compar
ttm basi
revenu growth ttm basi compar
oper margin decreas ttm basi compar due increas
ep declin ttm basi compar due decreas net margin
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth merck compani inc june
mrqgross mrqcog mrqoper mrqsg mrqnet mrqr sale merck compani inc june
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrqreturn mrqreturn mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale merck compani inc june
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item merck compani inc june
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free merck compani inc june
price-to-earnings trade averag price-to-earnings averag till even
went
current price-to-earnings fell averag price-to-earnings even touch
expect forward price-to-earnings multipl
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold direct holder form kenneth willi weir mirian robert adam michael juli richard institut holdersholdershar report outvaluevanguard group inc wellington manag compani capit world price row associ northern trust jp morgan top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf incom fund america washington mutual investor vanguard institut fund-institut vanguard specialized-health vanguard/wellington fund ishar fidel merck compani inc june
developmentsmerck keytruda pembrolizumab demonstr long-term surviv benefit base four year follow-up pivot studi advanc melanomamerck known msd outsid unit state canada announc long-term efficaci data phase studi melanoma cohort phase studi investig keytruda merck therapi patient advanc melanoma new analysi demonstr durabl efficaci benefit among patient complet two year keytruda treatment combin updat overal surviv os result across studi confirm anti-tumor activ advanc melanoma patient merck premier inc collabor help reduc clostridium difficil diff infectionmerck premier inc lead healthcar improv compani expand prevent chronic diseas care collabor includ new effort design help reduc recurr ofclostridium difficileinfect diff merck premier develop test combin software-bas platform coordin provid surveil consult support educ patient diff particip premier member health system goal increas patient access healthcar servic rais awar decreas patient risk recurr help patient identifi recurr fda grant prioriti review merck sbla keytruda pembrolizumab combin pemetrex alimta platinum chemotherapi base result fromphas trial first-lin treatment metastat nonsquam nsclcmerck announc food drug administr fda accept review supplement biolog licens applic sbla keytruda compani therapi base result phase trial applic seek approv keytruda combin pemetrex alimta platinum chemotherapi carboplatin cisplatin first-lin treatment patient metastat nonsquam non-smal cell lung cancer nsclc fda grant prioriti review sbla set prescript drug user fee act pdufa target action date sept receiv sustain excel awardmerck announc receiv partner year sustain excel award environment protect agenc epa continu leadership energi manag pharmaceut industri sector superior contribut merck accomplish recogn epa depart ceremoni washington april merck partner sinc recogn epa consecut year two time partner year time sustain excel june merck compani inc june
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
vs
price-to-earnings ratio ttm
industri
averag
gross margin ttm
industri
averag
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit merck compani inc june
consensu view analyst trend stock
forecast
lower
forward price-to-earnings
lower
mrk avgfive-year growth forecast usdgrowth high day day day estim comparisonmrkindustri avg avgprice/earn yield consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate analyst recommend
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
merck stock price show upsw trend quarter averag volum
merck gave return quarter current trade
merck stock price dip result octob result februari
due poor perform quarter
merck stock price increas april due develop product pipelin also due
strong perform
merck gave flat return past one year rang
stock show increas trend result reach
merck stock show upward trend april given return past three
merck strong start year due growth keytruda gardasil bridion anim
maintain buy rate stock tp base forward price-to-earnings
multipl non-gaap estim ep expect revenu grow
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
